Related Experiment Video
Updated: Feb 10, 2026

In Vitro Thrombosis Test for Ventricular Assist Devices
Published on: March 21, 2025
[Ventricular assist device and heart transplantation in Japan]
1Department of Cardiothoracic Surgery, Faculty of Medicine, The University of Tokyo, Tokyo 113-8655.
Insights
Ventricular assist devices (VADs) treat end-stage heart failure, offering options like bridging to transplant or permanent support. Japanese survival rates with the approved Toyobo VAD are improving, with ongoing trials for implantable devices.
Area of Science:
- Cardiology
- Medical Devices
- Surgical Technology
Context:
- End-stage heart failure management.
- Ventricular assist devices (VADs) serve as a bridge to transplantation, bridge to recovery, or destination therapy.
- Current VAD landscape in Japan includes approved paracorporeal devices and investigational implantable VADs.
Purpose:
- To review the application and outcomes of Ventricular Assist Devices (VADs) in treating end-stage heart failure.
- To compare survival rates of the approved Toyobo VAD in Japan with global heart transplantation data.
- To highlight the potential advantages and ongoing development of implantable VADs.
Summary:
- The paracorporeal Toyobo VAD, approved in Japan, shows improving survival rates (75% at 1 and 3 years, 58% at 5 years).
- Implantable VADs are under clinical trials in Japan, offering benefits like patient discharge and infection resistance.
- Japanese heart transplantation survival rates (98% at 1 and 3 years, 94% at 5 years) significantly exceed global averages.
Impact:
- Provides insights into VAD therapy effectiveness in Japan.
- Informs patients and clinicians about VAD options and outcomes.
- Highlights Japan's advanced position in heart transplantation success rates.
Abstract:
Ventricular assist device (VAD) has been applied for treatment of end-stage heart failure. Three major purposes of VAD are a bridge to transplantation, a bridge to recovery and a destination therapy (permanent VAD implantation). In Japan, only paracorporeal ventricular assist device (Toyobo-NCVC type) is approved for coverage by health insurance. Survival after Toyobo VAD implantation has been improving greatly Survivals 1, 3, 5-years after implantation are 75%, 75% and 58% respectively in our experience. Several implantable VADs are under clinical trials in Japan. Implantable VAD has many advantages, such as allowing patients to be discharged and being resistant to infection. Heart transplantation was performed in more than 70,000 cases worldwide. At present, approximately 3,000 transplantations were performed annually. Survivals after 1, 3, 5, 10-years are 86%, 79%, 72% and 51%. Fifty-seven heart transplantations were performed in Japan since 1999. Survivals after 1, 3, 5-years in Japan are 98%, 98% and 94%, which are far superior to world average results.
Related Concept Videos
Overview of the Heart
The heart's structure...
Conduction System of the Heart
The pacemaker cells are located in two primary nodes: the sinoatrial (SA) node and the atrioventricular (AV) node. The SA node pacemaker cells can autonomously depolarize, triggering an action potential that leads to the...
Anatomy of the Heart
Anatomy of the Heart
The heart has three layers: the innermost endocardium, the muscular myocardium, and the outer epicardium, all working together for optimal cardiac function.
Chambers of the Heart
The heart is made up of four...
Mnemonic Devices
Acronyms
Acronyms are created by using the initial letters of a series of words to form a new word or phrase. This approach condenses complex information into a single, memorable entity. For example,...
Non-ohmic Devices
Consider a simple circuit consisting of a battery, a diode, and a resistor. A...

